Friday Courses

Receive in-depth updates on the latest in GI and hepatology, endoscopy, and practice management when you attend one or more of the optional Friday courses. Six courses are offered: five half-day courses, the GI Pathophysiology Course, the What’s New in GI Pharmacology Course, the Practice Management Summit, and the ACG Advanced Practice Provider Leadership Summit; one evening course, the Guide to the Guidelines Course; and one full-day course, the ACG/ASGE Endoscopy Course.

GI Pathophysiology Course

Friday, October 24, 2025 | 1:00 pm – 6:30 pm Mountain Time

Course Directors: Darwin L. Conwell, MD, MS, FACG, Rachel B. Issaka, MD, and Joy J. Liu, MD

Friday, October 24, 2025 │ ALL TIMES ARE LISTED IN MOUNTAIN TIME (MT)
1:00 pm Welcome and Introductions
Darwin L. Conwell, MD, MS, FACG, Rachel B. Issaka, MD, and Joy J. Liu, MD
1:10 pm Eosinophils in the Esophagus: EoE, GERD, Motility
Nirmala Gonsalves, MD, FACG
Evaluate the current landscape of therapeutics to address eosinophilic disease in the esophagus including eosinophilic esophagitis, gastroesophageal reflux disease, and esophageal dysmotility based on underlying pathophysiology.
1:40 pm Updates in CRC
Rachel B. Issaka, MD
Describe the epidemiology of colorectal cancer (CRC), the latest understanding of underlying pathophysiology of polyp formation, genetics and early-onset CRC, and compare the underlying mechanisms between currently available and emerging CRC screening modalities.
2:10 pm Mechanisms of IBS and Refractory Constipation
Judy W. Nee, MD
Discuss the possible mechanisms of IBS-related pain including gut-brain interaction, evaluate the efficacy of brain-gut behavioral therapy and neuromodulators for managing IBS symptoms based on underlying pathophysiology, and describe mechanisms of refractory constipation, including pelvic floor dysfunction, and treatment approaches.
2:40 pm MASLD and Therapeutics in the Pipeline
Manal F. Abdelmalek, MD, MPH, FACG
Assess the pathophysiologic basis to changes in nomenclature and current treatment and therapeutic options for metabolic dysfunction-associated steatotic liver disease (MASLD), including both lifestyle interventions and weight loss medications.
3:10 pm Q & A
3:40 pm Break
4:00 pm Differentiating IBD Therapeutics: When to Choose a Biologic or Small Molecule
Anita Afzali, MD, MPH, MHCM, FACG
Discuss differences in biologics and small molecules including safety and effectiveness, selection of therapies based on patient factors.
4:30 pm The Microbiome in Functional Bowel Disease: How to Answer Patients’ Questions About SIBO and Leaky Gut
Eamonn M. M. Quigley, MD, MACG
Describe current understanding of the functions of the gut microbiome and metabolome in digestive health, how alterations may lead to disease processes, and provide updates in the understanding of mucosal integrity/epithelial barrier function and how this may pertain to GI symptoms and disease.
5:00 pm How to Manage Pancreatic Cysts
Somashekar G. Krishna, MD, MPH, FACG
Differentiate pancreatic cysts according to clinical features and diagnostic testing, and review current guidelines for the management and surveillance of pancreatic cysts.
5:30 pm Diets for GI Symptoms: Beyond Fiber and Low FODMAP
William D. Chey, MD, FACG
Discuss the pathophysiologic basis of food allergy versus food sensitivity and intolerance, interpret evidence regarding the low FODMAP diet and “SIBO diets,” and describe an integrated approach to managing GI symptoms using personalized dietary therapy.
6:05 pm Q & A
6:30 pm Course Adjourns